Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

Article  PubMed  Google Scholar 

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728

Article  PubMed  Google Scholar 

Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Di Leo A (2015) Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol 12(9):541–552

Article  PubMed  Google Scholar 

O’Shaughnessy J, Brezden-Masley C, Cazzaniga M, Dalvi T, Walker G, Bennett J, Ohsumi S (2020) Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Res 22(1):114

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu M, Xie F, Liu M, Zhang Y, Wang S (2021) Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 186(3):591–605

Article  CAS  PubMed  Google Scholar 

Li CH, Karantza V, Aktan G, Lala M (2019) Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res 21(1):143

Article  PubMed  PubMed Central  Google Scholar 

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31(12):1623–1649

Article  CAS  PubMed  Google Scholar 

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523–533

Article  CAS  PubMed  Google Scholar 

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753–763

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration: TALZENNA (talazoparib) [Label]. 2020

AstraZeneca: LYNPARZA (olaparib): EPAR - Product Information [Label]. 2020

Pfizer: TALZENNA (talazoparib): EPAR - Product Information [Label]. 2020

US Food and Drug Safety Administration: LYNPARZA (olaparib) [Label]. 2020

Cortesi L, Rugo HS, Jackisch C (2021) An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol 16(3):255–282

Article  PubMed  PubMed Central  Google Scholar 

China NMPA approves PARP inhibitor Pamiparib for patients with previously treated advanced ovarian cancer. https://ir.beigene.com/news-details/?id=305b6eb6-ecb3-426a-b382-4bda796d8c1f. Accessed 2 Dec 2022

Lynparza approved in China as a 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer. https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-china-as-a-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer.html#. Accessed 2 Dec 2022

Products. https://www.zailaboratory.com/products/. Accessed 2 Dec 2022

Im SA, Xu B, Li W, Robson M, Ouyang Q, Yeh DC, Iwata H, Park YH, Sohn JH, Tseng LM et al (2020) Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Sci Rep 10(1):8753

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, Wang X, Gao Y, Yu F, Su D et al (2020) Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia 22(9):431–440

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lickliter J, Mileshkin L, Voskoboynik M, Millward M, Friemund A, Meniawy T, Tang T, Wei R, Li M, Patron V (2017) 368PD: dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors. Ann Oncol 28:v123

Article  Google Scholar 

Xu B, Yin Y, Dong M, Song Y, Li W, Huang X, Wang T, He J, Mu X, Li L et al (2021) Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer. Cancer Med 10(1):109–118

Article  CAS  PubMed  Google Scholar 

Wu X, Zhu J, Wang J, Lin Z, Yin R, Sun W, Zhou Q, Zhang S, Wang D, Shi H et al (2022) Pamiparib monotherapy for patients with germline BRCA1/2-mutated ovarian cancer previously treated with at least two lines of chemotherapy: a multicenter, open-label, phase II study. Clin Cancer Res 28(4):653–661

Article  CAS  PubMed  Google Scholar 

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795

Article  PubMed  PubMed Central  Google Scholar 

Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013

Article  PubMed  Google Scholar 

Xu B, Hu X, Feng J, Geng C, Jin F, Li H, Li M, Li Q, Liao N, Liu D et al (2020) Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). Cancer 126(Suppl 16):3867–3882

Article  PubMed  Google Scholar 

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P et al (2018) Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 24(5):628–637

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA et al (2019) A phase II study of Talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO). Clin Cancer Res 25(9):2717–2724

Article  CAS  PubMed  Google Scholar 

Martín M, Eiermann W, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Yerushalmi R, Markova D, Tudor IC, Blum JL et al (2018) 303P—EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician’s choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Ann Oncol 29:viii96

Article  Google Scholar 

Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, Cao S, Li X (2018) Association between BRCA status and triple-negative breast cancer: a meta-analysis. Front Pharmacol 9:909

Article  PubMed  PubMed Central  Google Scholar 

Krammer J, Pinker-Domenig K, Robson ME, Gönen M, Bernard-Davila B, Morris EA, Mangino DA, Jochelson MS (2017) Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 163(3):565–571

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morice PM, Leary A, Dolladille C, Chrétien B, Poulain L, González-Martín A, Moore K, O’Reilly EM, Ray-Coquard I, Alexandre J (2021) Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol 8(2):e122–e134

Article  PubMed  Google Scholar 

Thein KZ, Sultan A, Zaw MH, Han MM, Yendala R, Zin MM, Awasthi S, D’Cunha N, Hardwicke F, Jones C (2018) Risk of secondary hematological malignancies and hematological toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance. Ann Oncol 29:viii343–viii344

Article  Google Scholar 

Htut T, Ball S, Swarup S, Sultan A, Han MM, Myat YM, Hardwicke FL, Tijani LA, Thein K (2020) Risk of secondary hematologic malignancies in patients with ovarian cancer treated with PARP inhibitors: a combined meta-analysis of seven phase III randomized controlled trials. J Clin Oncol 38(15_suppl):12076

Article  Google Scholar